Omega Therapeutics Inc   (OMGA)
Other Ticker:  
Price: $3.8900 $-0.40 -9.324%
Day's High: $4.27 Week Perf: 1.04 %
Day's Low: $ 3.83 30 Day Perf: 15.43 %
Volume (M): 716 52 Wk High: $ 10.09
Volume (M$): $ 2,784 52 Wk Avg: $4.74
Open: $4.26 52 Wk Low: $1.30

 Market Capitalization (Millions $) 214
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 2

Omega Therapeutics Inc
Omega Therapeutics Inc is a biotechnology company focused on developing therapies that target the human genome to treat various diseases. The company utilizes a novel approach called epigenomic programming, which involves modifying the gene expression patterns in cells to restore normal cellular function. Omega Therapeutics' therapies have the potential to address a wide range of diseases, including genetic disorders, cancer, and autoimmune conditions. The company aims to revolutionize the field of gene therapy and improve patient outcomes by targeting the underlying cause of diseases at the genetic level.

   Company Address: 140 First StreetSuite 501 Cambridge 2141 MA
   Company Phone Number: 949-4360   Stock Exchange / Ticker: NASDAQ OMGA
   OMGA is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Omega Therapeutics Inc

Breaking News: Biotech Giant Unveils Stellar Earnings for Q3 2023, Shaking the Markets

Omega Therapeutics Inc, a prominent player in the Biotechnology & Pharmaceuticals sector, released its financial results for the reporting period of July to September 30, 2023. The company showcased a positive performance, defying the downward trend observed across its industry. Omega Therapeutics reported a decrease in losses per share, an improved EPS, and a significant revenue jump. Additionally, the company's stock exhibited positive growth over the last five trading days.
Improved Financials
Over the July to September 30, 2023 interval, Omega Therapeutics Inc recorded a loss per share of $-0.40, showcasing a marked improvement from the loss per share of $-0.54 reported a year ago. Moreover, the company witnessed an increase in EPS from $-0.54 to $-0.40 per share from the previous reporting period.

Omega Therapeutics Inc

Omega Therapeutics Inc Soars with Profound 59.454% Revenue Boost in Fiscal Q2, Leading in the Biotech & Pharma Sector

Omega Therapeutics Inc's stock has experienced significant gains over the past week, increasing by 15.73%. Additionally, compared to the previous year, the stock has seen an improvement of 31.53%. However, it is currently trading on the NASDAQ at a 12.4% lower price than its 52 week average.
Examining the company's financial performance, Omega Therapeutics Inc reported a loss of $-0.54 per share in the fiscal second quarter of 2023. This represents no change from the previous year, but it is an increase from the loss of $-0.50 per share in the previous reporting period. Despite the loss per share remaining relatively constant, the company's revenue showed strong growth. In the comparable reporting period a year prior, revenue increased by 59.454% to $0.76 million from $0.48 million. Sequentially, revenue surged by 47.093% from $0.52 million.

Omega Therapeutics Inc

Omega Therapeutics Inc. Surges with 92% Revenue Increase, Despite Challenging Period

Investors in Omega Therapeutics Inc. have faced a challenging financial period for the year ending March 31, 2023, as the company posted a higher loss per share and net loss compared to the previous year. However, there is some good news as the company managed to increase its revenue by 92.537% to $0.52 million from $0.27 million a year prior.
Despite the sequential drop in revenue by -29.7% from the previous reporting period, the increase is significant and could lead to potential growth opportunities for the company. However, based on the figures, it is clear that the company still has a long way to go to break even.


Omega Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com